These promising results led to an open label phase I multicycle dose escalation study seeking to recruit 60 patients with PCa, who will be subdivided in three groups according to prior treatment with chemotherapy, androgen receptor pathway inhibitors, and [177Lu]Lu-PSMA-617 TRNT (AcTION, NCT04597411) [102]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.